ReviewHayati : journal of biosciences2017
Emerging Developments on Pathogenicity, Molecular Virulence, Epidemiology and Clinical Symptoms of Current Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
Review in Hayati : journal of biosciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 19 citations in OpenAlex.
- A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases.Journal of nanobiotechnology · 2022Review
- Insights into the structural properties of SARS-CoV-2 main protease.Current research in structural biology · 2022Article
- Article
- Article
- Middle East Respiratory Syndrome (MERS) Virus-Pathophysiological Axis and the Current Treatment Strategies.AAPS PharmSciTech · 2021Review
- A comparative genomics-based study of positive strand RNA viruses emphasizing on SARS-CoV-2 utilizing dinucleotide signature, codon usage and codon context analyses.Gene reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) is a recently reported virus that is associated with severe, life threatening and rapidly spreading primarily respiratory illness called the Middle East respiratory syndrome. MERS-CoV possesses a unique positive-sense single-stranded RNA and can undergo rapid mutation in the viral genome. This results in antigenic switching and genetic variation, finally leading to the emergence of novel and new MERS-CoV subtypes which are uncontrollable by vaccines. Researchers are also finding difficulties to sort out therapeutic intervention strategies for MERS-CoV. This virus can spread from human to human, but transmission from dromedary camels to humans plays a crucial epidemiological significance. Dromedary camel acts as "gene mixing vessels" for MERS-CoV and these virus particles undergo rapid change in them. Viral receptors called dipeptidyl peptidase-4 are important receptors for attachment and spread of MERS-CoV in humans. The current method of laboratory confirmation is through real-time polymerase chain reaction on bronchoalveolar lavage, sputum and tracheal aspirates. Unfortunately, till today there are no definite anti-viral drugs available for MERS-CoV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.